Voice of Regenerative Medicine : Biomed Realty Trust Inc (BMR), a Public Company that has Failed to Disclose its Legal Proceedings to SEC and the Public against SEC Regulations and Public Policy, is Making False Accusations, Alleging Defamation Lawsuit, and Threatening Restraining Order and Injunction to Bully Human Embryonic Stem Cell Research Blog and Private Sectors for Speaking Truth about BMR’s Deliberate Destruction to Human Embryonic Stem Cells and Damages to Private Life Science Startup

Wednesday, October 22, 2014

Biomed Realty Trust Inc (BMR), a Public Company that has Failed to Disclose its Legal Proceedings to SEC and the Public against SEC Regulations and Public Policy, is Making False Accusations, Alleging Defamation Lawsuit, and Threatening Restraining Order and Injunction to Bully Human Embryonic Stem Cell Research Blog and Private Sectors for Speaking Truth about BMR’s Deliberate Destruction to Human Embryonic Stem Cells and Damages to Private Life Science Startup – What BMR Has to Hide?

All the information disclosed below is privileged and provided by BMR, SDRMI, and other sources through case discovery. This blog makes no representations as to accuracy, completeness, correctness, reliability, suitability, or validity of this information. The content on this blog is the opinion only, not intended to malign any religion, ethnic group, club, organization, company, or individual, or anyone or anything.

BioMed Realty Trust Inc (BMR), a public traded company advertising itself as the world largest commercial real estate specializing in leasing laboratory spaces to life science industry, has failed to disclose its legal proceedings to the United States Security and Exchange Commission (SEC) and the Public in consecutive quarterly reports against SEC regulations and Public Policy (please see http://www.sec.gov/ and image files of BMR SEC reports below). BMR’s board members include trustees and president of Salk Institute; trustee of Stanford University; CEO of Amylin Pharmaceuticals; boards of directors of Illumina, Geron Corporation, Alliance Pharmaceutical Corp, Corcept Therapeutics, and Castle Biosciences; the advisory councils of the University of California San Diego and the University of Miami; President of Roth Capital (please see http://www.biomed.com ). BMR’s biotechnology company investment portfolio includes some of the trailblazers in human embryonic stem cell lines, such as Geron and Asterias Biotherapeutics, a subsidiary of Biotime, which dosed on stem cell assets of Geron in October 2013 under a ~ $40 million deal for acquiring four cell lines, including OPC1, that were shelved by Geron. Asterias entered into an 8-year lease contract with BMR in January 2014 that worth ~$1.5 million/year, and subsequently, received a $14.3 million award from California Institute for Regenerative Medicine (CIRM) in May 2014 to continue clinical trial of OPC1 for spinal cord injury abandoned by Geron in November 2011.

BMR, a public-traded company, has been a party of multiple legal proceedings including case#37-2013-00038680 and case#37-2012-00042147 (court records can be viewed at http://www.sdcourt.ca.gov), which disclosed through case discoveries BMR’s shocking malicious intention and despicable conducts in illegal confiscation and destruction of valuable human embryonic stem cell lines and stem cell research materials of San Diego Regenerative Medicine Institute (SDRMI) – a privately-hold stem cell startup in life science industry, and illegal confiscation and sell of stem cell research equipment of SDRMI with its partner organizations through fraudulent lease against public policy, invalid legal documents, false statements in legal documents under the penalty of perjury under the laws of the State of California, default and judgment that contain multiple legal deficiencies, and failure to follow proper legal procedures. However, BMR has reported to SEC repeatedly during last consecutive quarters that BMR is not currently a party to any legal proceedings nor is any legal proceeding threatened against BMR that BMR believe would have a material adverse effect on its financial position, results of operations or liquidity against SEC regulations (please see http://www.sec.gov/ and image files of BMR SEC reports below). To cover up that BMR has violated public policy and government regulations to deliberately withhold information about its legal proceedings and multiple legal deficiencies to SEC and the Public, BMR is making false accusations and alleging defamation lawsuit (Case#37-2014-00034661, court records can be viewed at http://www.sdcourt.ca.gov, please see image files provided by BMR themselves below), threatening restraining order and injunctions to bully Voice of Regenerative Medicine – a human embryonic stem cell research blog – and extort private sector unrelated individuals and startups for speaking truth about BMR’s legal proceedings that contain multiple legal deficiencies; violates the legal rights, ownership, and privacy of US private organizations and citizens, including US veteran and POW, entitled by law; and resulted in deliberate destruction to human embryonic stem cells of SDRMI and devastating damages to private life science startup (case#37-2013-00038680, case#37-2012-00042147, and case#37-2014-00034661, court records can be viewed at http://www.sdcourt.ca.gov, please see image files and BMR attorney’s frequent ex parte contacts and extortionate demand letters provided by BMR themselves below). What BMR, a public company that has failed to disclose its legal proceedings to SEC against public policy and government regulations, has to hide from SEC, the public, and the share holders?

BMR provided the supporting documents below.

No comments:

Post a Comment

Public Interest

The successful derivation of human embryonic stem cell (human ES cell) lines from the in vitro fertilization (IVF) leftover embryos is considered as one of the major breakthroughs of the life sciences. The pluripotent human ES cells, derived from the inner cell mass (ICM) or epiblast of human blastocyst or human embryos, have both the unconstrained capacity for long-term stable undifferentiated growth in culture and the intrinsic potential for differentiation into all somatic cell types in the human body, holding tremendous potential for human tissue and function restoration. Therefore, human ES cells have been regarded as an ideal source to provide an unlimited supply of large-scale well-characterized human specialized cell types for cell-based therapies to resolve some worldwide major health problems, such as neurodegenerative diseases, paralysis, diabetes, and heart diseases. A small portion of the millions of excess embryos currently stored in the IVF clinics worldwide, which are otherwise destined for destruction, could potentially be an unlimited source to deliver in the future a whole range of therapeutic treatments for tissue and function restoration in patients with life-threatening diseases and injuries. However, human ES cell research has generated intense public interest as well as controversy due to concerns of products of human ES cell cultures that can only be obtained by the use, involving their destruction, of human embryos. The recent years’ court battles on Federal funding for human ES cell research in the United State (US) as well as the patentability of US and international patents directed to human ES cell technologies have also highlighted the decade long ethical, moral, social, and legal controversy surrounding the public interest of human ES cells involving destruction, commercial or industrial uses of human embryos. As neurodegenerative and heart diseases incur exorbitant costs on the healthcare system worldwide, there is a strong focus on providing newer and more efficient solutions for these therapeutic needs. Millions of people are pinning their hopes on human ES cell research. California voters have passed Proposition 71 to designate $3B public fund to support pluripotent human ES cell research and therapy development for the benefit of public health. In spite of ethical debates surrounding the ownership and funding issues of human ES cells, in the case of many incurable or hitherto untreatable life-threatening or devastating diseases, supporting human ES cell research is crucial to driving the advance of medicine to provide optimal regeneration and reconstruction treatment options to improve the function, wellness, and overall quality of life. To answer the intense public interest surrounding human ES cell research and enormous public healthcare benefits thereof, Voice of Regenerative Medicine provides a ground of public debate or voice or blog for the controversies surrounding public interest of human ES cells centering on scientific, economic, ethical, moral, social, financial conflict of interest, and legal issues, to increase public awareness and understanding of the scientific advancement of human ES cell research, and of the importance, urgency, and tangible benefits of human ES cell-based regenerative medicine to improving the function, wellness, and overall quality of life for patients suffering from incurable or hitherto untreatable life-threatening or devastating diseases; to increase public support for human ES cell research; to improve policy making and funding situation for human ES cell research, and to identify and disclose publicly those scientific, economic, ethical, moral, social, financial conflict of interest, and legal issues that have impeded the progress of human ES cell research and stem cell therapy development, introduction of medical innovations and new business opportunities based on human ES cell research, and bringing new therapeutics into the market.

Disclaimer:

This “Voice of Regenerative Medicine” blog is to provide a public voice and an open forum to human embryonic stem cell research and regenerative medicine start-up. All content provided on this blog is for informational purposes only. This blog makes no representations as to accuracy, completeness, correctness, reliability, suitability, or validity of any information on this site or found by following any link on this site, and will not be liable for any errors or omissions or availability in this information, or any losses, injuries, or damages arising from the display or use of this information. The inclusion of any content, images, documents, files, and links on the blog does not necessarily imply a recommendation or endorse the views expressed within them. The content of any postings or comments on the blog do not necessary reflect or do not necessary represent the positions, strategies, views, or opinions of the owners, authors, bloggers, or San Diego Regenerative Medicine Institute or any organizations or any companies or any director, officer, or employee thereof. This blog is not associated with, affiliated with, a partner with, belonging to, or acting upon any organizations or individuals. The blog’s content is not generated to make money or paid for blogging content. It is natural for the content on the blog to be controversial or contentious. The content on the blog is the opinion only, not intended to malign any religion, ethnic group, club, organization, company, or individual, or anyone or anything. The owners, bloggers, San Diego Regenerative Medicine Institute, any individuals, any organizations, and any companies are not responsible, nor will be held liable, for the content or comments or the display or use of any information on the blog. Our intention is to do no harm, to not injure others, defame, or libel. All information is provided on an as-is basis. These terms and conditions are subject to change at anytime and without notice.